Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Celerion and BryanLGH Health System Form Alliance to Provide Dedicated Hospital Beds for Phase I Studies

Celerion and BryanLGH Health System Form Alliance to Provide Dedicated Hospital Beds for Phase I Studies

(Lincoln, NE; Dec 9, 2010) –Celerion, the premier provider of innovative early stage clinical research solutions, and BryanLGH Health System, a locally owned, non-profit healthcare organization, announce an alliance to provide a dedicated wing at BryanLGH Medical Center West in Lincoln, Nebraska for early clinical studies including Phase I and First-In-Human.

This exclusive alliance will provide pharmaceutical, and biotechnology companies the opportunity to place clinical studies in a hospital environment, thus increasing safety for study volunteers and improving access to hospital procedures and techniques for studies placed at Celerion’s Lincoln clinical facility. Celerion will have access to 24 in-patient beds, in the newly launched Celerion-BryanLGH Clinical Research Unit. Celerion will leverage over forty years experience conducting clinical studies and will incorporate the same staff, global standard operating procedures and institutional review board, ensuring consistency across all studies executed at our sites.

“Improving safety for participants in clinical studies, while getting drugs to market faster, is critical to pharmaceutical companies”, said Philip Bach, Vice President, Clinical Research at Celerion. “This alliance will allow Celerion to conduct studies in a hospital environment, providing round-the-clock emergency care. Celerion will also strengthen their capabilities with access to state-of-the-art hospital techniques and equipment, such as chest X-rays, PET scans, and MRIs, for studies executed at our clinical facility in Lincoln, Nebraska.”

“We are very pleased to collaborate with Celerion on this venture. Celerion’s staff is among the best in the industry, with extensive experience and expertise – going back to its founding in Lincoln in 1933 as Harris Labs”, said Kimberly A. Russel, President and CEO at BryanLGH. “This alliance affirms a major commitment by BryanLGH Health System to clinical research and is a natural extension of our medical expertise. We will safely help get drugs to market faster, which will benefit everybody.”

BryanLGH is one of only 74 hospitals in the United States to have received both the 2010 Distinguished Hospital Award for Clinical Excellence™ and the Patient Safety Excellent Award™ from HealthGrades®.

About Celerion

Celerion is the premier provider of innovative early stage clinical research solutions. It was formed through the acquisition of the early stage development operations and development and regulatory services consultancy of MDS Pharma Services.

The company offers a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. From facilities strategically located around the world, Celerion applies advanced scientific and technological expertise to clinical research (Phases 0, I and IIa), bioanalytical services (discovery through late stage), clinical pharmacology sciences and drug development services.

For more information, visit

About BryanLGH

BryanLGH Health System includes BryanLGH Medical Center, Crete Area Medical Center, BryanLGH Heart Institute, BryanLGH Physician Network, LifePointe by BryanLGH and the BryanLGH Foundation.

BryanLGH Medical Center is a 664-bed, not for profit, locally owned, healthcare organization serving patients from throughout Nebraska, as well as parts of Kansas, Iowa, South Dakota and other states in the region. Premier services include cardiology, neuroscience, orthopedics, vascular, trauma and emergency centers, intensive care, women’s and children’s health, imaging, and mental health. BryanLGH College of Health Sciences offers graduate and undergraduate degrees through its School of Nursing, School of Health Professions and School of Nurse Anesthesia.

BryanLGH received the Gold Seal of Approval from the Joint Commission on Accreditation of Healthcare Organizations, which sets the highest standards for quality and safety in the delivery of health care.

For more information, visit